Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo
| Autor: | Dirschka, T, Radny, P, Dominicus, R, Mensing, H, Brüning, H, Jenne, L, Karl, L, Sebastian, M, Oster-Schmidt, C, Klövekorn, W, Reinhold, U, Tanner, M, Gröne, D, Deichmann, M, Simon, M, Hübinger, F, Hofbauer, G, Krähn-Senftleben, G, Borrosch, F, Reich, K, Berking, C, Wolf, P, Lehmann, P, Moers-Carpi, M, Hönigsmann, H, Wernicke-Panten, K, Helwig, C, Foguet, M, Schmitz, B, Lübbert, H, Szeimies, R M |
|---|---|
| Přispěvatelé: | University of Zurich, Foguet, M |
| Rok vydání: | 2011 |
| Předmět: |
Adult
Aged 80 and over Male Photosensitizing Agents Adolescent 10177 Dermatology Clinic Pain 610 Medicine & health Aminolevulinic Acid Middle Aged Administration Cutaneous 2708 Dermatology Keratosis Actinic Young Adult Treatment Outcome Photochemotherapy Patient Satisfaction Humans Female Gels Aged Pain Measurement |
| Zdroj: | The British journal of dermatology. 166(1) |
| ISSN: | 1365-2133 |
| Popis: | Photodynamic therapy (PDT) with 5-aminolaevulinic acid (ALA) or its methylester [methyl-5-aminolaevulinate (MAL) or 5-amino-4-oxopentanoate] was recently ranked as first-line therapy for the treatment of actinic keratosis (AK) and is an accepted therapeutic option for the treatment of neoplastic skin diseases. BF-200 ALA (Biofrontera Bioscience GmbH, Leverkusen, Germany) is a gel formulation of ALA with nanoemulsion for the treatment of AK which overcomes previous problems of ALA instability and improves skin penetration.To evaluate the efficacy and safety of PDT of AKs with BF-200 ALA in comparison with a registered MAL cream and with placebo.The study was performed as a randomized, multicentre, observer-blind, placebo-controlled, interindividual trial with BF-200 ALA, a registered MAL cream and placebo in a ratio of 3:3:1. Six hundred patients, each with four to eight mild to moderate AK lesions on the face and/or the bald scalp, were enrolled in 26 study centres in Germany, Austria and Switzerland. Patients received one PDT. If residual lesions remained at 3months after treatment, PDT was repeated.PDT with BF-200 ALA was superior to placebo PDT with respect to patient complete clearance rate (78·2% vs. 17·1%; P0·0001) and lesion complete clearance rate (90·4% vs. 37·1%) at 3months after the last PDT. Moreover, superiority was demonstrated over the MAL cream regarding the primary endpoint patient complete clearance (78·2% vs. 64·2%; P0·05). Significant differences in the patient and lesion complete clearance rates and severity of treatment-related adverse events were observed for the narrow- and broad-spectrum light sources.BF-200 ALA is a very effective, well-tolerated new formulation for AK treatment with PDT and is superior to a registered MAL medication. Efficacies and adverse events vary greatly with the different light sources used. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text